Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: A randomised, controlled, open-label, phase 4, non-inferiority study

The Lancet Infectious Diseases

Volumn 15, Issue 11, 2015, Pages 1273-1282

  O'Ryan, Miguel ^a   Bandyopadhyay, Ananda S ^b   Villena, Rodolfo ^a   Espinoza, Mónica ^a   Novoa, José ^a   Weldon, William C ^c   Oberste, M Steven ^c   Self, Steve ^d   Borate, Bhavesh R ^d   Asturias, Edwin J ^e   Clemens, Ralf ^f   Orenstein, Walter ^g   Jimeno, José ^h   Rüttimann, Ricardo ⁱ   Costa Clemens, Sue Ann ^j   Aviles, Jimena Guzmán ^k   Rojas, Felipe Yagnam ^k   Cubillos Celis, Maria Paz ^k   de Quiroz, Marcela Campos ^k   O'Ryan Soriano, Miguel ^k   Escobar, Beatriz Cathalifaud ^k   Alliende, Catalina Frias ^k   Niemann, ShuyLing Chang ^k   Calderón, Ana Fernández ^k   Herrera, Jessica Delgado ^k   Brunet, Camilo Novoa ^k   Gonzalez, Denise Acevedo ^k   Aros, Paulina Pacheco ^k   Yañez, Luis Espinosa ^k   Bello, Camila Vera ^k   more..

^a UNIVERSITY OF CHILE   (Chile)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d USA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f Global Research in Infectious Diseases   (Brazil)

^g EMORY UNIVERSITY   (United States)

^h Vaxtrials   (Panama)

ⁱ Fighting Infectious Diseases in Emerging Countries (FIDEC)   (United States)

^j Instituto de Pós Graduação Médica Carlos Chagas   (Brazil)

^k Instituto de Pós Graduação Carlos Chagas ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; INACTIVATED VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BIRTH WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN POLIOVIRUS 1; HUMAN POLIOVIRUS 2; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INTENTION TO TREAT ANALYSIS; INTESTINE INTUSSUSCEPTION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROTYPE; TREATMENT DURATION; VACCINATION; VIRUS SHEDDING; BLOOD; CHILE; CLINICAL TRIAL; FECES; IMMUNIZATION; IMMUNOLOGY; NORMAL HUMAN; POLIOMYELITIS; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ANTIBODIES, VIRAL; CHILE; FECES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; TREATMENT OUTCOME; VACCINATION; VIRUS SHEDDING;

EID: 84945456582     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00219-4     Document Type: Article

References (20)

1. Bandyopadhyay AS, Garon J, Seib K, Orenstein WA Polio vaccination: past, present and future. Future Microbiol 2015, 10:791-808.
2. Minor P Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27:2649-2652.
3. Platt LR, Estivariz CF, Sutter RW Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014, 210(suppl 1):S380-S389.
4. Polio vaccines: WHO position paper, January 2014-recommendations. Vaccine 2014, 32:4117-4118. WHO.
5. OMS declara alerta por poliomielitis: en Chile está erradicada desde Minsterio de Salud, (accessed Jan 25, 2015). http://vacunas.minsal.cl/?p=424.
6. Report of a WHO informal consultation on polio neutralizing antibody assays 1991, WHO, World Health Organization, Geneva, WHO/EPI/RD/91.3.
7. WHO. Expanded program on immunization. Manual for the virological investigation of polio. 1997. WHO EPI/GEN/97.01.EPV1.
8. Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
9. Fay MP, Shaw PA Exact and asymptotic weighted logrank tests for interval censored data: The interval R package. J Stat Soft 2010, 36:1-34.
10. Polio Laboratory Manual 2004, World Health Organization. 4th edition.
11. Kilpatrick DR, Iber JC, Chen Q, et al. Poliovirus serotype-specific VP1 sequencing primers. J Virol Methods 2011, 174:128-130.
12. Karber G Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. Naunyn-Schmeidebergs Arch Exp Path Pharmakol 1931, 162:480-483.
13. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012-conclusions and recommendations. Wkly Epidemiol Rec 2013, 88:1-16. WHO.
14. Deshpande JM, Nadkarni SS, Siddiqui ZA Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 and 2003. Indian J Med Res 2003, 118:217-223.
15. Dayan GH, Thorley M, Yamamura Y, et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007, 195:12-20.
16. Anand A, Pallansch MA, Estivariz CF, Gary H, Wassilak SGF Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys. J Infect Dis 2014, 210(suppl 1):S465-S474.
17. John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014, 384:1505-1512.
18. Sabin AB Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus. J Exp Med 1952, 96:99-106.
19. Ashkenazi A, Melnick JL Heterotypic antibody response after feeding on monovalent attenuated live poliovaccine. N Engl J Med 1962, 267:1228-1230.
20. Wright PF, Wieland-Alter W, Ilyushina NA, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis 2014, 209:1628-1634.